Marketresearchnews

Monday, 14 June 2021

Sternal Closure Systems Market to Witness Widespread Expansion During 2020-2027

Market Highlights

The Sternal Closure Systems Market Report is expected to register a CAGR of 5% and reach USD 2500 million during the forecast period. Open heart surgery has been a huge success today. Sternum closure systems are used to close the sternum and are the last step in open heart surgery. This technique involves steel wires that are wrapped around the halves of the sternum to close it. The global sternal closure systems market is majorly driven by, rising geriatric populations, abuse of alcohol and drugs, the high prevalence of cardiac diseases, and growing penetration of key market players. Furthermore, raising awareness of healthcare, favorable reimbursement policies, increasing advanced technical devices, increasing innovations in research and development of medical devices, as well as rising average income of individuals, are fueling the market growth. However, factors such as high cost of devices, complicated and costly surgical procedures involved and risks of getting infected due to sternum closure devices are likely to hamper the growth of the market. Lack of proper healthcare infrastructure, as well as awareness regarding cardiac diseases in middle-income countries, is a major challenge to the market growth.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/6137

Key Players

Some of the key players in the Sternal closure systems market are Depuy Synthes, Zimmer Biomet Holdings, Orthofix International N.V., A&E Medical, Kinamed Incorporated, Abyrx, Jace Medical, Jeil Medical Corporation, and Acute Innovations

Segmentation

The global sternal closure systems market is segmented on the basis of product type, procedure, closure material type and end-user. According to the product type, the market is segmented closure devices and bone cement. Closure devices are further segmented into wires, plates & screws, clips, and cables.

Considering the type of procedure, the market is segmented into median sternotomy, bilateral thoracosternotomy, hemisternotomy, and others.

According to the closure material type, the market is segmented into stainless steel, titanium, and others.

On account of end-user, the market is segmented into, hospitals & clinic, research institutes, and others.

Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.

Regional Analysis

Americas is the global leader for Sternal closure systems market owing to increasing prevalence of cardiovascular diseases among adults and older population. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising demand for technologically advanced treatment are likely to enhance the growth of sternal closure systems market in the American region. For instance, according to the Centers for Disease Control and Prevention, every year about 610,000 people in America are a victim of heart diseases and annually about 735,000 Americans suffer due to heart attacks. This alarming rate of cardiovascular disorders is expected to have a direct effect on the growth of sternal closure systems market as it finds whole and sole application in cardiovascular disorders. Presence of pharmaceutical giants like Pfizer, Merk, etc. also propels the market growth in this region.

Europe is the second largest market and holds a healthy share in the global sternal closure systems market. The European market is expected to grow during the forecast period due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure along with growing need for better healthcare infrastructure and government initiatives of healthcare reform. For instance, according to 2017 statistics presented by the European Society of Cardiology, there were more than 6 million reported new cases of cardiovascular diseases in the European Union and more than 11 million in Europe as a whole. Hence cardiovascular disease being one of the major concern in Europe contributes significantly to the market growth of this region. Additionally, Europe spent around 210 Euros in 2015 for treatment of cardiovascular disorders. This rising healthcare expenditure due to cardiovascular disorders is expected to have a positive impact on the sternal closure systems market. But the popularity of minimally invasive procedures, as well as risks associated with open heart surgery and close sternum devices, may hamper the market growth.

Asia Pacific is expected to be the fastest growing market. According to report published by the United Nations in 2015; between 2015 and 2030, the number of older persons aged 60 years or over in the world is predicted to grow by 56 %, out of which 66% of the older population would reside in Asia-Pacific regions. This makes the region prone to metabolic disorders that would further aid the chances of cardiovascular. Owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, availability favorable insurance and reimbursement policies market growth will be accelerated during the forecast period. Moreover, with key players like Boston Scientific Corporation, Pfizer, Merck, etc. have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia growth curve of sternal closure systems market will see a positive trend.

On the other hand, the Middle East and Africa is expected to witness a slow growth due to limited access to healthcare facilities and affordability issues among the population. In the Middle East, the growth of the market is driven by Saudi Arabia and the United Arab Emirates because of the well-established healthcare infrastructure, awareness for good health among the residents, as well as accessibility to modern medical technology methods.

Access Report @ https://www.marketresearchfuture.com/reports/sternal-closure-systems-market-6137

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Multiplex Assays Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

Multiplex Assays Market Overview:

Multiplex Assays are used to detect multiple analytes in a single run of the assay. These are widely used in genomics to quantify mRNAs, DNAs, and proteins to assess the effect of DNA mutation on various biomolecules in the given sample. With multiplex assays, scientists can gain more information about a single protein or series of proteins within a single well or reaction of an experiment. This not only helps the scientists to conserve time and cost but also save on their sample quantity. Researchers are using multiplex assays to detect cellular regulatory events occurring in chronic diseases such as cancer.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/6135

Key players

Some of the key players for the global Multiplex Assays Market Trends are Luminex, Thermo Fisher Scientific, Illumina, Bio-Rad Laboratories, Qiagen, Abcam, Becton Dickinson and Company, Merck, Agilent Technologies, Meso Scale Diagnostics, Randox Laboratories, Quanterix, Bio-Techne, Olink, Seegene, and others.

Segmentation

The global multiplex assays market is segmented on the basis of product and service, type, technology, application, and end-user. The multiplex assays market, by product and service, is sub-segmented into consumables, instruments, software and services, and others. On the basis of type, the market is categorized into protein multiplex assays, nucleic acid multiplex assays, cell-based multiplex assays, and others. Protein multiplex assays are further sub-segmented into planar protein assays, bead-based protein assays, and others. Nucleic acid multiplex assays are further sub-segmented into planar nucleic acid assays, bead-based nucleic acid assays, and others. The technology segment includes flow cytometry, fluorescence detection, luminescence, real-time multiplex PCR, and others. On the basis of application, the market is categorized into research and development and clinical diagnostics. The research and development segment includes drug discovery and development and biomarker discovery and validation. The clinical diagnostics segment includes infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, metabolism and endocrinology disorders, and others. On the basis of end-user, the market is segmented into pharmaceutical and biotechnology companies, hospitals and research institutes, reference laboratories, and others.

Regional Analysis:

The multiplex assay market is dominated by North America due to increase in R&D activities and rising R&D expenditure in this region. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), the U.S. carries out nearly half of the world's pharmaceutical Research and Development (R&D) and possesses the intellectual property rights on most of the newly developed medicines, thus driving the market growth in this region.

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

New research report offers detailed research on developments in Aseptic Sampling Market 2027

Aseptic Sampling Market – Overview

The booming biopharmaceutical industry is a key factor driving the demand for the aseptic sampling market. Market reports connected with the healthcare industry are being offered by Market Research Future which creates reports on other business verticals that defines the present market scenarios. The market is projected to advance with a formidable CAGR of 14.5% in the duration of the forecast period.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/6282

The escalating usage and implementation of single-use aseptic sampling systems are powering the expansion of the market. Furthermore, the progressing nature of process efficiency and reduction in the risk of product contamination is anticipated to motivate the expansion of the aseptic sampling market in the coming years.

Segmental Analysis

The segmentation of the Aseptic Sampling Market Trends comprises of application, type, technique, region, and end-user. The segmentation of the aseptic sampling market has been on the basis of type comprises of automated aseptic sampling and manual aseptic sampling. The aseptic sampling market segmentation by technique comprises of on-line sampling, off-line sampling technique, and at-line sampling. On the basis of application, the market has been segmented into downstream process and upstream process. Based on end-user, the aseptic sampling market has been segmented into research and development institutes, pharmaceutical and biotechnology companies, and contract research and manufacturing organizations. The regional basis of segmenting the aseptic sampling market comprises of the Asia Pacific, Americas, Europe, Africa, and the Middle East.

Competitive Analysis

Improved accessibility to diverse resources and capabilities is expected to impel the growth of the market in the coming forecast period. The use of effective strategy execution techniques is anticipated to bear positively on the future growth of the market. Furthermore, the vertical integrations and product strategies of the market is increasing the potential for the market players. The players in the market are attempting to create several leaderships that will allow them to secure a more substantial portion of the market. Product differentiation has formed a favorable product differentiation situation that is adding to the market’s progress. The analysis of the market states that it is poised for an increased growth rate in the forthcoming years.

The main competitors in the aseptic sampling market globally are Sartorius Stedim Biotech, Qualitru Sampling Systems, Thermo Fisher Scientific, Danaher Corporation, Flownamics Analytical Instruments, Saint Gobain, GEA Group, Merck KGaA, Keofitt, Gemü Group, W. L. Gore & Associates, Lonza Group, Trace Analytics, and Bürkle GmbH.

Detailed Regional Analysis

The regional analysis of the aseptic sampling market includes regions such as the Asia Pacific, Americas, Europe, Africa, and the Middle East. The European region is predicted to rule the aseptic sampling market globally. The market development in this region is accredited to the growing R&D activities and the budding biopharmaceutical sector. Furthermore, the governments in numerous European countries are backing pharmaceutical companies to unveil new biopharmaceutical products. This factor is anticipated to add to the development of the market. The Americas region is projected to be the next principal market in aseptic sampling owing to the stringent government regulations on safety and quality of pharmaceutical products and the incidence of a steady healthcare system.

Furthermore, the growing government spending for the healthcare sector is projected to back the market development in this region. The Asia Pacific region is projected to be the fastest rising market due to the mounting developments in healthcare infrastructure and increasing number of regional expansions by multinational biopharmaceutical companies. The Middle Eastern and African region is projected to be responsible for the least market share in the aseptic sampling market owing to the subdued development, the absence of technical knowledge, and weak medical facilities in emerging economies in this region.

Access Report @ https://www.marketresearchfuture.com/reports/aseptic-sampling-market-6282

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Recombinant Vaccines Market Growth, Trends and Value Chain 2020-2027

Recombinant Vaccines Market Information: By Product (Subunit Recombinant and Attenuated Recombinant Vaccines), by Disease (Cancer, Pneumococcal Disease, Hepatitis B, and DPT), and End-Users (Pediatrics, Adults, and Veterinary) – Global Forecast Till 2027

Market Highlights

The recombinant vaccines market size is expected to exhibit a CAGR of 6.8% during the forecast period. Vaccines that are produced using recombinant DNA technology or genetic engineering are called recombinant vaccines. The recombinant vector vaccine strategy enables triggering of T- cells or B-cells thus generating a strong cell-mediated or humoral immune response in the body against that particular immunogen. The global recombinant vaccines market is majorly driven by increasing technical advanced research, increasing number of regulatory approvals, the high prevalence of infectious diseases and growing penetration of key market players. Furthermore, raising awareness of good health, favorable reimbursement policies, increasing innovations in research and development of drugs and vaccines as well as rising average income of individuals is propelling the market growth. However, factors such as high cost of vaccines, risks associated with live attenuated vaccines and stringent regulatory policies are likely to restrict the growth of the market. Lack of proper health care infrastructure, as well as awareness regarding opportunistic pathogen-related diseases in middle-income countries, are a major challenge to the market growth.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/6130

Key Players:

Some of the key players in the Recombinant Vaccines Market Analysis are Abiomed, Emergent Bio Solutions, Inc., GlaxoSmithKline, Johnson & Johnson, Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo, and Pfizer, Inc.

Segmentation

The global recombinant vaccines market is segmented on the basis of product type, diseases, and end-user. According to the product, the market is segmented into subunit recombinant vaccines, attenuated recombinant vaccines, and vector recombinant vaccines,

Considering the disease type, the market is segmented into pneumococcal disease, cancer, hepatitis B, influenza, DPT, and others.

On account of end-user, the market is segmented into hospitals & clinics, pediatrics, adults, veterinary, and others. Veterinary is further segmented to poultry and livestock.

Based on the region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.

Regional Analysis

Americas is the top market leader in the recombinant vaccines market owing to increasing advances in research in the field of molecular biology and genetic engineering as well as increasing prevalence of infectious diseases and cancer. Additionally, factors such as increasing government initiatives and funding for research, development of advanced medical treatment options, and rising demand for technologically advanced treatment are likely to enhance the growth of recombinant vaccines market in the American region. For instance, according to the stats presented by breast cancer organization about 12.4% of U.S. women are prone to develop invasive breast cancer over the course of her lifetime. Raising global burden of cancer has also led a lot of key players to invest their time and money to come up with solutions to curb this problem. For instance, the vaccine therapy with or without trastuzumab as well as GM-CSF vaccine for the treatment of breast cancer is in phases II clinical trial. Green signal from regulatory bodies for these vaccines will further boost up the market growth.

Europe is the second largest market and holds a healthy share in the global recombinant vaccines market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure along with the alarming rate of cancer and infectious diseases. Furthermore, Lots of established key players in this region export their products to the developing nation. For instance, the European Commission stated that the R&D spending by the pharmaceuticals and biotechnology sectors grew by 8.7% in 2014. This investment in R&D along with the ongoing legislative reforms is expected to have a positive impact on the recombinant vaccines market.

Asia Pacific is expected to be the fastest growing market owing to the faster adaptation of healthcare technology, increasing patient pool due to cancer and infectious diseases, government initiatives to increase the healthcare quality, favorable insurance, and reimbursement policies. Key players have set up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia thus, boosting the growth of recombinant vaccines market. Government is also taking several initiatives to spread awareness in the low-income areas. As most of the developing country due to their poor hygienic conditions and large populations are more prone to infectious diseases, they have launched compulsory immunization program against influenza, DPT, measles, and Hepatitis B and C.

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. The Middle East has the largest market share owing to the development of healthcare industry and rising availability of specialty care centers in the United Arab Emirates and Saudi Arabia.

Access Report @ https://www.marketresearchfuture.com/reports/recombinant-vaccines-market-6130

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Research report explores the Radiation Protection Apparels Market for the forecast period, 2020-2027

It is estimated that the global Radiation Protection Apparels Market Share is expected to register a market value of USD 473 million in 2017, with a CAGR ~ 7.2% during the forecast period of 2018–2027.

Several factors such as increase in strict safety regulations by various government agencies such as Occupational Safety and Health Administration (OSHA), and National Institute for Occupational Safety and Health (NIOSH), and increase in the number of medical imaging processes are luring the growth of the market. However, high price of apparels, and detrimental effect of aprons on the health of the wearer are some of the factors curbing the growth of this market.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/7451

The global radiation protection apparels market is currently dominated by many market players. The major players in the market are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in May 2015, Ansell Limited acquired Microgard, a protective clothing manufacturer. With this acquisition, the company aims to increase its product portfolio and expand its geographical presence.

Key Players

Some of the key players in the global radiation protection apparels market are Kiran, Ultraray, Scanflex medical AB, MAVIG GmbH, Barrier Technologies, Biodex Medical Systems, Inc., CABLAS S.R.L, Lite Tech, Inc., Protech Medical, Rego X-ray GmbH, Shielding International, Inc., and Teijin Limited.

Segmentation

The global radiation protection apparels market has been segmented into product type, material, and end user.

The market, based on product type, has been segmented into aprons, gloves, head shields, thyroid shields, and others.

The market, by material, has been segmented into lead free, lead-based, light weight lead composite, and others.

The market, by end user has been segmented into hospitals and clinics, research laboratories, and others.

Regional Analysis

The market in the Americas is expected to dominate the global radiation protection apparels market during the forecast period owing to the presence of regulatory mandates. In addition, proactive government initiatives to spread awareness about the benefits of radiation protection apparel among the masses have supplemented the market growth. Europe is expected to hold the second largest position in the global radiation protection apparels market. The market growth in this region is because of the presence of a well-established healthcare system and increase in reimbursement policies. Asia-Pacific is estimated to be the fastest growing region in the market due to the improved healthcare infrastructure in the region. The market in the Middle East & Africa is likely to account for the smallest share of the global radiation protection apparels market.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/radiation-protection-apparels-market-7451

Porcine Vaccines Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

Segmentation

The global porcine vaccines market has been segmented into type, disease indication, and end user.

By type, the market has been segmented into Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines.

On the basis of disease indication, the global porcine vaccines market has been segmented into PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine influenza, Aujeszky's disease (AD), Porcine Circovirus Associated Disease (PCVAD) and others.

The global porcine vaccines market, by end user, has been segmented into Veterinary Hospitals and Hog Production Farm.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/7438

Market Highlights

The global Porcine Vaccines Market Trends held a market value of USD 1910.7 million in 2017 and is projected to grow at a CAGR of 7.1% over the forecast period. Porcine vaccines aid the swine or hogs suffering from epidemic swine diseases. It also helps in improving overall efficiency in protecting swine from deadly viruses, bacteria and increases the production level of high-quality meat and gelatine. The increasing prevalence of swine diseases such as PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), swine influenza etc. are anticipated to drive the market growth during the forecast period. Additionally, rising number of biotechnology companies, research institutions engaged in research and development of porcine vaccines, and government initiatives for funding agriculture and animal husbandry sector and increasing demand for porcine meat and gelatine are likely to contribute to the market growth. For instance, by the world by per-capita pig meat consumption, US has an average of 64.4 kilos of meat consumed in 2017. According to National Pork Producers Council the pork production has an estimated USD 23.4 billion of gross output nationwide. However, high cost of maintaining vaccines may hamper the market growth during the assessment period.

Key Players

Some of the prominent players in the global porcine vaccines market are Bayer AG, Bimeda, Inc., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Vetoquinol S.A., Zoetis, Inc., PBS Animal Health, Aptimmune.

Regional Analysis

On regional basis, the Americas is anticipated to dominate the global porcine vaccines market owing to the increasing prevalence of porcine diseases such as PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), swine influenza etc. and rapid increase in pig farms. Additionally, rise in number of contract farming and independent farming for pig cultivation is contributing the market growth. According to The United States Department of Agriculture, National Agricultural Statistics Service “Livestock Slaughter” report, U.S. pork production was around 2 billion pound in 2016. Europe is expected to hold the second largest position in the global porcine vaccines market owing to increasing number of production units for pigs and high consumption of pork meat. The Asia-Pacific region is anticipated to be fastest growing region is due to introduction of new vaccines, initiatives by various government agencies, animal care associations, and incidence of major key players for growth and development in this region. The Middle East & Africa has the least share of the global porcine vaccines market. Moreover, the major market share of the region is expected to be held by the Middle East region owing to the increasing government initiatives for the agriculture and animal husbandry sector.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/porcine-vaccines-market-7438

3D Bioprinting Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

The global 3D Bioprinting Market Share is projected to touch USD 1,923.02 million by 2027, asserts Market Research Future (MRFR). The market can showcase an impressive 24.59% CAGR from 2018 to 2027 (forecast period) to reach this value. It was previously valued at USD 517.97 million in 2017.

Increasing demand for organ transplantation is projected to drive market demand year-on-year till 2027. This is attributed to the paucity of organs available for transplants. In 2014, nearly 120,000 people were on the waiting list for organs. This opportunity can be capitalized by the 3D bioprinting market by manufacturing customized organs according to body size.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/869

Investments in 3D bioprinting via public and private means to widen its scope is likely to boost the market growth. For instance, Tekes, the Finnish Funding Agency for Innovation, awarded funds to the University of East Finland to develop a fully functioning 3D brain for research purposes. Moreover, cost-efficiency of 3D bioprinted products is likely to lead to renewed interest by investors.

Lack of awareness of the technology and shortage of skilled professionals can act as growth deterrents in the market.

Competitive Analysis:

Prominent names in the 3D Bioprinting Market are Nano3D Biosciences Inc. (U.S.), REGENHU Ltd. (Switzerland), FUJIFILM Wako Automation Corporation (U.S.), Allevi (U.S.), Organovo Holdings Inc. (U.S.), Regenovo Biotechnology Co. Ltd. (China), Aspect Biosystems Ltd. (Canada), Stratasys Ltd. (U.S.), Poietis (France), Cellink AB (Sweden), EnvisionTEC GmbH (Germany), and Cyfuse Biomedical K.K. (Japan).

Segmentation Analysis:

The 3D bioprinting market is segmented by technology, material, application, and end-user.

By technology, microextrusion bioprinting held close to 31.7% share in 2017, followed by inkjet 3D bioprinting (25.1%), laser-assisted bioprinting (20.6%), magnetic 3D bioprinting (13.7%), and others (8.9%). The microextrusion bioprinting segment is projected to register a whopping 25.24% CAGR during the forecast period. This can be attributed to its extensive applications in bioprinting. On the other hand, inkjet 3D bioprinting can exhibit 26.44% CAGR owing to being a viable alternative for scaffold fabrication.

By material, living cells accounted for 39.7% share in 2017, followed by hydrogels (30.8%), extracellular matrices (21.0%), and others (8.5%). Living cells are predicted to exhibit 25.05% CAGR during the forecast period thanks to the expedited production process of micro building blocks. The blocks play a vital role in repairing damaged tissues. Hydrogels, on the other hand, can generate close to USD 652.54 million by 2027 at a CAGR of 26.63% during the forecast period.

Among applications, research applications accounted for 73% share in 2017, followed by clinical applications with 27% share in the same year. Research applications can exhibit 24.74% CAGR till 2027 owing to applications in 3D cell culture and regenerative medicine. Clinical applications, on the other hand, can generate close to USD 507.55 million by 2027, at a 24.19% CAGR during the assessment period.

Among end-users, pharmaceutical & biotechnology companies accounted for 52.6% share in 2017, followed by research organizations & academic institutes (33.3%), and others (14.1%). Pharmaceutical & biotechnology companies are projected to display 24.98% CAGR till 2027 owing to the trend in personalized medicines.

Regional Analysis:

Region-wise, the 3D bioprinting market is segmented into Europe, Americas, Asia Pacific (APAC), and the Middle East & Africa (MEA). Americas held close to 38.1% market share in 2017, followed by Europe (31.8%), APAC (23.2%), and MEA (6.9%).

The Americas region is touted to touch a valuation of USD 689.91 million by 2027. This can be attributed to investments in research and development, presence of developed healthcare infrastructure, and massive demand for organs among the patient pool. Furthermore, development of 3D printed pills which can be customized according to person age and body weight is likely to open up growth opportunities for the 3D bioprinting market to expand in the region.

The APAC region can grow at a rapid pace owing to developments in the healthcare sector, development in 3D printing, and abundance of opportunities. The region can garner close to USD 507.18 million by 2027 at a CAGR of 27.25% during the forecast period. In addition, government funding to accelerate the pace of 3D printing technology can bode well for the market.

The Europe 3D bioprinting market can touch a value of USD 649.91 million by 2027 owing to increased focus on health and wellness. Rise in cosmetic surgery demand is likely to play a huge role for the market’s progress in the region. Agreements between prime players to expedite the evolution of the technology can net novel results. This is exemplified by the deal signed between BASF SE and Poietis to improve skin care products by the former.

Browse Full Report @ https://www.marketresearchfuture.com/reports/3d-bioprinting-market-869